Cargando…

Effects of Chinese Herbal Medicine on Acute Exacerbations of COPD: A Randomized, Placebo-Controlled Study

PURPOSE: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an essential occurrence in COPD management and is the leading cause of morbidity and mortality. Chinese herbal medicine is widely used in the treatment of AECOPD, but high quality randomized controlled trials are limite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jiansheng, Zhang, Hailong, Ruan, Huanrong, Si, Yimei, Sun, Zikai, Liu, Hong, Feng, Jihong, Wang, Yanqing, Li, Lihua, Bai, Li, Sun, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670171/ https://www.ncbi.nlm.nih.gov/pubmed/33209019 http://dx.doi.org/10.2147/COPD.S276082

Ejemplares similares

Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial
por: Zhang, Hailong, et al.
Publicado: (2019)

Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study
por: Ma, Jinfang, et al.
Publicado: (2018)

Assessment of Completeness of Reporting in Randomized Controlled Trials of Acupuncture Therapy for Chronic Obstructive Pulmonary Disease
por: Ruan, Huanrong, et al.
Publicado: (2022)

Effects of Chinese herbal medicine Xiangbin prescription on gastrointestinal motility
por: Jiang, Zhi, et al.
Publicado: (2017)

A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD
por: Cowan, Juthaporn, et al.
Publicado: (2021)

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation
por: Calverley, Peter MA, et al.
Publicado: (2019)

Effect of Panax Ginseng (G115) Capsules versus Placebo on Acute Exacerbations in Patients with Moderate to Very Severe COPD: A Randomized Controlled Trial
por: Chen, Yuanbin, et al.
Publicado: (2020)

Bacterial lysate add‐on therapy to reduce exacerbations in severe asthma: A double‐blind placebo‐controlled trial
por: de Boer, Geertje M., et al.
Publicado: (2021)

Effects of Empirical Glucocorticoid Use on Severe Acute Exacerbation of COPD During Hospitalization
por: Wu, Ling, et al.
Publicado: (2021)

Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial
por: Willcox, Merlin L., et al.
Publicado: (2023)

The Anti-Inflammatory Effect of a Combination of Five Compounds From Five Chinese Herbal Medicines Used in the Treatment of COPD
por: Li, Jiansheng, et al.
Publicado: (2021)

All-cause readmission rate and risk factors of 30- and 90-day after discharge in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
por: Ruan, Huanrong, et al.
Publicado: (2023)

Changes in ventilation–perfusion during and after an COPD exacerbation: an assessment using fluid dynamic modeling
por: Hajian, Bita, et al.
Publicado: (2018)

Prevalence of Pulmonary Embolism and Deep Venous Thromboembolism in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Han, Weihong, et al.
Publicado: (2022)

Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study
por: Liu, Xia, et al.
Publicado: (2023)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2020)

The Impact of COPD Exacerbations in the Year Following Pulmonary Rehabilitation: Secondary Analysis of a Randomised Controlled Trial
por: Wageck, Bruna, et al.
Publicado: (2020)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2022)

Combining systems pharmacology, transcriptomics, proteomics, and metabolomics to dissect the therapeutic mechanism of Chinese herbal Bufei Jianpi formula for application to COPD
por: Zhao, Peng, et al.
Publicado: (2016)

Bu-Fei Yi-Shen Granules Reduce Acute Exacerbations in Patients with GOLD 3–4 COPD: A Randomized Controlled Trial
por: Yu, Xue-Qing, et al.
Publicado: (2023)

Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD
por: Zhao, Peng, et al.
Publicado: (2015)

Chinese Herbal Therapy for Chronic Tension-Type Headache
por: Tong, YanQing, et al.
Publicado: (2015)

An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules
por: Han, Mei, et al.
Publicado: (2019)

Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients
por: Xing, Yu-Feng, et al.
Publicado: (2020)

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
por: Xu, Binghe, et al.
Publicado: (2023)

Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial
por: Hu, Xiao-Yang, et al.
Publicado: (2022)

Exposure to Air Pollution Exacerbates Inflammation in Rats with Preexisting COPD
por: Wang, Jing, et al.
Publicado: (2020)

Effect of traditional Chinese medicine on outcomes in patients with mild/moderate chronic obstructive pulmonary disease: study protocol for a randomized placebo-controlled trial
por: Minghang, Wang, et al.
Publicado: (2012)

Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial
por: Li, Yinjuan, et al.
Publicado: (2020)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
por: Liu, Chao, et al.
Publicado: (2019)

Efficacy and safety of traditional Chinese medicine in patients with acute exacerbation of idiopathic pulmonary fibrosis: study protocol for randomized, controlled, exploratory clinical trial
por: Hailong, Zhang, et al.
Publicado: (2022)

Placebo design in WHO-registered trials of Chinese herbal medicine need improvements
por: Zhang, Xuan, et al.
Publicado: (2019)

AGR3 Regulates Airway Epithelial Junctions in Patients with Frequent Exacerbations of COPD
por: Ye, Rui, et al.
Publicado: (2021)

Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study
por: Fahy, William A, et al.
Publicado: (2021)

Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound
por: Su, Xuefeng, et al.
Publicado: (2016)

Identifying patterns of kinesiophobia trajectories among COPD patients: A longitudinal study
por: Liang, Facun, et al.
Publicado: (2023)

Exacerbations of COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Exacerbations of COPD
por: Viniol, Christian, et al.
Publicado: (2018)

Efficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials
por: Cai, Xiaoce, et al.
Publicado: (2022)

Real-World COPD Management Over 3 Years at the Community Health Service Center of Shanghai During the COVID-19 Pandemic in China
por: Wu, Ting-Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tj5g2l8iul182fj81bnica54o7